<?xml version="1.0"?>
<oembed><version>1.0</version><provider_name>Department of Medicine</provider_name><provider_url>https://www.med.unc.edu/medicine</provider_url><author_name>Deb Hepp</author_name><author_url>https://www.med.unc.edu/medicine/news/author/debbhepp/</author_url><title>Medicine Grand Rounds, Kenneth Ataga, "Pharmacological Therapies for Sickle Cell Disease: Beyond Hydroxyurea" | Department of Medicine</title><type>rich</type><width>600</width><height>338</height><html>&lt;blockquote class="wp-embedded-content" data-secret="CSomCDEpYB"&gt;&lt;a href="https://www.med.unc.edu/medicine/event/sept-21/"&gt;Medicine Grand Rounds, Kenneth Ataga, &#x201C;Pharmacological Therapies for Sickle Cell Disease: Beyond Hydroxyurea&#x201D;&lt;/a&gt;&lt;/blockquote&gt;&lt;iframe sandbox="allow-scripts" security="restricted" src="https://www.med.unc.edu/medicine/event/sept-21/embed/#?secret=CSomCDEpYB" width="600" height="338" title="&#x201C;Medicine Grand Rounds, Kenneth Ataga, &#x201C;Pharmacological Therapies for Sickle Cell Disease: Beyond Hydroxyurea&#x201D;&#x201D; &#x2014; Department of Medicine" data-secret="CSomCDEpYB" frameborder="0" marginwidth="0" marginheight="0" scrolling="no" class="wp-embedded-content"&gt;&lt;/iframe&gt;&lt;script type="text/javascript"&gt;
/* &lt;![CDATA[ */
/*! This file is auto-generated */
!function(d,l){"use strict";l.querySelector&amp;&amp;d.addEventListener&amp;&amp;"undefined"!=typeof URL&amp;&amp;(d.wp=d.wp||{},d.wp.receiveEmbedMessage||(d.wp.receiveEmbedMessage=function(e){var t=e.data;if((t||t.secret||t.message||t.value)&amp;&amp;!/[^a-zA-Z0-9]/.test(t.secret)){for(var s,r,n,a=l.querySelectorAll('iframe[data-secret="'+t.secret+'"]'),o=l.querySelectorAll('blockquote[data-secret="'+t.secret+'"]'),c=new RegExp("^https?:$","i"),i=0;i&lt;o.length;i++)o[i].style.display="none";for(i=0;i&lt;a.length;i++)s=a[i],e.source===s.contentWindow&amp;&amp;(s.removeAttribute("style"),"height"===t.message?(1e3&lt;(r=parseInt(t.value,10))?r=1e3:~~r&lt;200&amp;&amp;(r=200),s.height=r):"link"===t.message&amp;&amp;(r=new URL(s.getAttribute("src")),n=new URL(t.value),c.test(n.protocol))&amp;&amp;n.host===r.host&amp;&amp;l.activeElement===s&amp;&amp;(d.top.location.href=t.value))}},d.addEventListener("message",d.wp.receiveEmbedMessage,!1),l.addEventListener("DOMContentLoaded",function(){for(var e,t,s=l.querySelectorAll("iframe.wp-embedded-content"),r=0;r&lt;s.length;r++)(t=(e=s[r]).getAttribute("data-secret"))||(t=Math.random().toString(36).substring(2,12),e.src+="#?secret="+t,e.setAttribute("data-secret",t)),e.contentWindow.postMessage({message:"ready",secret:t},"*")},!1)))}(window,document);
/* ]]&gt; */
&lt;/script&gt;
</html><thumbnail_url>https://www.med.unc.edu/medicine/wp-content/uploads/sites/945/2018/12/kenneth-ataga.jpeg</thumbnail_url><thumbnail_width>188</thumbnail_width><thumbnail_height>250</thumbnail_height><description>Dr. Ataga is the director of the UNC Comprehensive Sickle Cell Program. His clinical research is focused on the vasculopathy of sickle cell disease, with an emphasis on pulmonary hypertension and renal complications, and coagulation activation in sickle cell disease. In addition, he has a strong research interest in the development of new therapies for &hellip; Read more</description></oembed>
